Skip to main content
    M

    MAIA Biotechnology Inc. (MAIA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.00
    +0.00 (+0.00%)

    Market Cap: $61.75M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MAIA Biotechnology Inc. (MAIA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    MAIA Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$22.40M, operating cash flow was -$18.84M and free cash flow was -$18.84M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.18M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $24.27M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Research and development$14.55M$10.01M$11.11M$8.62M$3.45M$1.41M$1.91M
    Operating income-$24.27M-$16.96M-$20.18M-$16.18M-$7.79M-$6.98M-$6.92M
    Net income-$22.40M-$23.25M-$19.77M-$15.77M-$12.58M-$6.64M-$6.49M
    EBITDA-$22.76MN/A-$19.80M-$16.08MN/A-$6.97M$242
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$8.02M-$8.32M-$6.95M-$4.32M-$9.36M-$5.17M-$5.43M-$5.00M-$4.19M-$3.82M-$3.95M-$6.38M
    Net income-$7.18M-$7.94M-$6.37M-$3.63M-$8.90M-$5.35M-$4.52M-$3.57M-$2.74M-$8.88M-$8.07M-$6.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $8.66M were 89.3% of total assets of $9.70M, against total liabilities of $7.33M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$9.70M$10.16M$7.57M$12.02M$11.33M$746.50K$1.73M
    Current assets$9.70M$10.15M$7.56M$11.81M$10.67M$746.50K$1.73M
    Cash and equivalents$8.66M$9.60M$7.15M$10.95M$10.57M$663.46K$1.71M
    Total liabilities$7.33M$6.52M$7.09M$3.51M$2.15M$2.36M$409.74K
    Short-term debtN/AN/AN/AN/A$111.27K$31.95K$25.00K
    Long-term debtN/AN/AN/AN/AN/A$431.80KN/A
    Shareholder equity$2.38M$3.63M$477.51K$8.51M$9.18M-$3.34M-$172.87K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$22.10M$28.24M$35.32M$9.70M$11.78M$11.05M$11.86M$10.16M$9.24M$12.02M$8.72M$7.57M
    Total liabilities$7.43M$7.57M$7.56M$7.33M$11.74M$7.17M$6.92M$6.52M$7.62M$8.86M$14.48M$7.09M
    Cash and equivalents$21.34M$27.60M$34.41M$8.66M$10.89M$10.14M$10.86M$9.60M$8.69M$11.58M$8.27M$7.15M
    Shareholder equity$14.67M$20.68M$27.76M$2.38M$41.67K$3.88M$4.94M$3.63M$1.62M$3.16M-$5.76M$477.51K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$18.84M-$15.70M-$13.07M-$12.10M-$4.12M-$1.84M-$1.57M
    Capital expenditures$0$0$4$0$0$0$2
    Free cash flow-$18.84M-$15.70M-$13.07M-$12.10M-$4.12M-$1.84M-$1.57M
    Dividends paidN/AN/AN/AN/AN/A$58.21KN/A
    Investing cash flow$0$0$0$0$0N/A$187.56K
    Financing cash flow$17.91M$18.18M$9.27M$12.48M$14.03M$798.05K$2.22M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.31M-$6.75M-$5.31M-$7.02M-$3.49M-$4.14M-$4.20M-$3.91M-$3.52M-$4.68M-$3.59M-$3.99M
    Capital expendituresN/AN/A$2$4$0$4$4$5$1$1$0$0
    Free cash flowN/AN/A-$5.31M-$7.02M-$3.49M-$4.14M-$4.20M-$3.91M-$3.52M-$4.68M-$3.59M-$3.99M
    Last 12 quarters

    Frequently Asked Questions About MAIA

    What is MAIA Biotechnology's annual revenue?

    MAIA Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is MAIA Biotechnology profitable?

    No. MAIA Biotechnology reported net income of -$22.40M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MAIA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.84M minus capital expenditures of $0 produced free cash flow of -$18.84M.

    How much debt does MAIA Biotechnology have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $8.66M.